Lvr
Alcoholic Hepatitis
search
Alcoholic Hepatitis
, Alcoholic Liver Disease, Acute Alcoholic Hepatitis
See Also
Cirrhosis
Acute Hepatitis
Hepatotoxin
Liver Function Test Abnormality
Acute Hepatic Failure
(
Fulminant Hepatitis
)
Viral Hepatitis
Epidemiology
Alcoholic Hepatitis seen in 33% of chronic
Alcohol
ics
Accounted for 0.8% of hospital admissions in U.S., 2010
Precautions
Acute Alcoholic Hepatitis, although often asymptomatic, may be severe and life threatening
Pathophysiology
Chronic Alcoholic Hepatitis is a precursor to
Cirrhosis
Characteristics
Hepatocyte Inflammation, degeneration, and necrosis
Neutrophil
and
Lymphocyte
infiltration
Risk Factors
Prolonged and heavy
Alcohol
use
Female gender
Younger age
Family History
High
Body Mass Index
Comorbid liver disease
HIstory
Substance Use
See
Substance Abuse Evaluation
See
Alcoholism Screening
Tools
AUDIT-C
CAGE Questions
NIAAA Quantity and Frequency Questionnaire
Symptoms
Acute Alcoholic Hepatitis
Anorexia
Nausea
and
Vomiting
Weight loss
Fever
Fatigue
Malaise
Abdominal Pain
Generalized Abdominal Pain
Epigastric Pain
Right Upper Quadrant Abdominal Pain
Signs
Acute Alcoholic Hepatitis
Tender
Hepatomegaly
(80-90% of cases)
Jaundice
Ascites
Splenomegaly
Other findings or chronic stigmata may be present
Spider Angioma
Confusion (
Hepatic Encephalopathy
)
Loss of
Muscle
mass
Peripheral Neuropathy
Day night reversal
Labs
Alcoholic Hepatitis Diagnostic findings
Total
Serum Bilirubin
>3 mg/dl (>51.3 uMol/L)
Transaminase increase (
Aspartate Aminotransferase
,
Alanine Aminotransferase
)
AST >50 U/L (>0.83 ukat/L) AND
AST/ALT >1.5 AND
AST <400 U/L (<6.68 ukat/L) AND
ALT <400 U/L (<6.68 ukat/L)
Other liver test findings
Prolonged INR (or
ProTime
)
Alkaline Phosphatase
elevated
Gamma glutamyl transferase
(GGT) markedly elevated
Hypoalbuminemia (decreased
Serum Albumin
and
Serum Prealbumin
)
Complete Blood Count
White Blood Cell Count
increased (mean 12.4k, but may range up to 20k)
Mean Corpuscular Volume
(MCV) elevated (Macrocytosis)
Thrombocytopenia
Diagnosis
Criteria (all must be present)
No confounding factors (see below)
Jaundice
onset within prior 8 weeks
Total
Serum Bilirubin
>3 mg/dl (>51.3 uMol/L)
Transaminase increase
AST >50 U/L (>0.83 ukat/L) AND
AST/ALT >1.5 AND
AST <400 U/L (<6.68 ukat/L) AND
ALT <400 U/L (<6.68 ukat/L)
Heavy
Alcohol
Use for >6 months (and <60 days of abstinence) before
Jaundice
onset
Women with 3 standard drinks per day (>40 g)
Men with 4 standard drinks per day (>60 g)
Confounding Factors (possible alternative diagnoses)
Ischemic Hepatitis
Severe upper gastrointestinal
Hemorrhage
Hypotension
Cocaine
use within 7 days of symptom onset
Metabolic liver disease
Wilson Disease
Hemochromatosis
Alpha-1-Antitrypsin Deficiency
Drug-Induced
Liver
Disease
Use of suspected
Hepatotoxin
within 30 days of
Jaundice
onset
Uncertain
Alcohol
use assessment
Patient denies use that meets above criteria
Atypical lab findings (consider alternative diagnosis)
AST <50 U/L (<0.83 ukat/L)
AST/ALT <1.5
AST or ALT >400 U/L (>6.68 ukat/L)
Autoimmune liver disease findings
Antinuclear Antibody
>1:160
Anti-
Smooth Muscle Antibody
>1:80
Other confounding and comorbid conditions
Viral Hepatitis
Biliary obstruction
Confirmatory Testing
Liver
biopsy
Indicated if possible confounding factor diagnosis would alter management
Noninvasive measures are preferred in other cases
Arab (2021) Clin Liver Dis 25(3):571-84 +PMID:34229840 [PubMed]
References
Crabb (2020) Hepatology 71(1):306-33 +PMID: 31314133 [PubMed]
Management
Gene
ral Measures
See
Prevention of Liver Disease Progression
Alcohol
Cessation
See
Alcoholism Management
See
Alcohol Withdrawal Protocol
Nutritional Management
Increased caloric and
Protein
intake
Vitamin Supplement
ation
Thiamine
Folate
Multivitamin
Manage comorbidities
Treat acute infections
Consider empiric broad spectrum
Antibiotic
s until cultures are negative
High
Incidence
of comorbid acute infection in Alcoholic Hepatitis
Management
Severe Alcoholic Hepatitis
Indications
Maddrey Discriminant Function
Score >= 32 or
MELD Score
>=21
Precautions
Management below assumes that any acute infections have been fully treated and resolved
Corticosteroid
s (
Prednisolone
)
Efficacy: Improves survival (n=61)
Two month survival 88% versus 45% with
Placebo
Improved survival persists for 1 year
No advantage after 1 year
References
Mathurin (1996) Gastroenterology 110:1847-53 [PubMed]
Protocol
Avoid
Corticosteroid
s until acute infections are excluded (including negative cultures)
Start
Corticosteroid
s
Prednisolone
40 mg orally daily or
Methylprednisolone
32 mg IV daily
Reevaluate for
Corticosteroid
responsiveness at 7 days with Lille Score
https://www.mdcalc.com/lille-model-alcoholic-hepatitis
Lille Score >0.45: Failed
Corticosteroid
trial
Stop
Corticosteroid
s
Refer for early
Liver Transplant
(see below)
Lille Score <0.45:
Corticosteroid
Responsive
Complete 28 day course of
Corticosteroid
s, then taper off
Liver Transplant
Indications
MELD Score
>=21
Spontaneous Bacterial Peritonitis
episode
Comorbid
Hepatocellular Carcinoma
Alcohol
associated liver disease
No improvement after 3 months of abstaining from
Alcohol
Child-Pugh Class
C (10 to 15)
New onset of decompensated liver disease
Hepatic Ascites
Hepatic Encephalopathy
Jaundice
Bleeding Esophageal Varices
Complications
Infection
Spontaneous Bacterial Peritonitis
Urinary Tract Infection
Pneumonia
Enterocolitis
Cellulitis
Chronic comorbidities
Esophageal Varices
(
Portal Hypertension
)
Hepatic Ascites
Esophageal Varices
Hepatorenal Syndrome
Prognosis
Acute Alcoholic Hepatitis
Maddrey Discriminant Function
predicts patients at highest risk of death
Severe Alcoholic Hepatitis mortality 16 to 30% at 28 days (56% at one year)
Chronic Alcholic Hepatitis
Cirrhosis
develops in 50% of chronic Alcoholic Hepatitis patients
References
Hill (1998) Postgrad Med 103(4):261-275 [PubMed]
Keating (2022) Am Fam Physician 105(4): 412-20 [PubMed]
Type your search phrase here